Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody.

The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in patients with obesity.

It will assess parameters increasingly viewed as important to the long-term quality and/or sustainability of weight loss, including gastrointestinal tolerability (GI) and lean mass retention.

“There is clearly a need for alternative mechanisms of action that can provide physicians and patients with improved overall health outcomes in the pursuit of weight loss beyond those achieved with GLP-1 and GIP drugs. We believe that peripheral CB1 inhibition, and nimacimab, a unique biologic drug within the class, have attributes that may help provide such outcomes, and we look forward to our goals of reporting interim data from this Phase II obesity trial in Q2 of 2025 and final data in Q4 of 2025,” said Punit Dhillon, Chief Executive Officer of Skye.

“CB1 inhibition research has shown its potential to directly promote energy expenditure and fat breakdown, improve leptin sensitivity, and peripherally modulate hunger and satiety.”

Assessing psychiatric effects of CB1 inhibition

The clinical trial will enrol 120 patients across four treatment groups. Eighty patients will receive either nimacimab 200mg or nimacimab-matching placebo subcutaneously once-weekly. Forty patients will receive either nimacimab + Wegovy or nimacimab-matching placebo + Wegovy once-weekly.

“As we evaluate CB1 inhibition as a possible alternative mechanism for weight loss, we believe it is important to consider health outcomes beyond GI intolerance and muscle loss, such as neuropsychiatric adverse events, that may compromise the long-term use of these drugs that is necessary for sustainable results,” added Tu Diep, Chief Development Officer of Skye.

“The first-generation CB1 inhibitor, rimonabant, was a small molecule that acted on the CNS. While showing efficacy in reducing weight, it also indicated dose-related psychiatric adverse events, including anxiety, depressed mood, depression and suicidality. We believe that nimacimab’s positive safety and tolerability profile places Skye at a competitive advantage over small molecule CB1 inhibitors.”

The trial’s primary endpoint is a difference in mean weight loss of 8% between active and placebo with 80% power. The secondary endpoints are safety and tolerability,neuropsychiatric and cognitive evaluation, change in body composition by dual-energy X-ray absorptiometry (DEXA).

The trial will also investigate the change in key metabolic parameters including triglycerides, insulin sensitivity, and leptin sensitivity, as well as the difference in weight loss between nimacimab and Wegovy.

Diana Spencer, Senior Digital Content Editor, DDW